4.61
-0.34(-6.87%)
Currency In USD
| Previous Close | 4.95 |
| Open | 5.06 |
| Day High | 5.6 |
| Day Low | 4.57 |
| 52-Week High | 80.5 |
| 52-Week Low | 3.6 |
| Volume | 290,408 |
| Average Volume | 70,720 |
| Market Cap | 32.01M |
| PE | -0.22 |
| EPS | -21.35 |
| Moving Average 50 Days | 8.9 |
| Moving Average 200 Days | 25.29 |
| Change | -0.34 |
If you invested $1000 in Scilex Holding Company (SCLX) since IPO date, it would be worth $13.37 as of April 30, 2025 at a share price of $4.61. Whereas If you bought $1000 worth of Scilex Holding Company (SCLX) shares 2 years ago, it would be worth $12.93 as of April 30, 2025 at a share price of $4.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025
GlobeNewswire Inc.
Apr 22, 2025 1:00 PM GMT
PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products fo
Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis
GlobeNewswire Inc.
Apr 16, 2025 6:12 PM GMT
Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Pericarditis is an inflammation of the pericardium, the sac-like membrane that surrounds and prote
Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s Acute Treatment of Migraine With or Without Aura in Canada
GlobeNewswire Inc.
Apr 15, 2025 1:00 PM GMT
ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1According to market data from 2018, it was found that migraine was more severe than other ty